We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
Read MoreHide Full Article
Key Takeaways
Intuitive Surgica's Ion procedures rose 36% year over year to 48,000 in the second quarter.
Ion's installed base grew 21%, while availability expanded to 12 countries outside the United States.
ROSE and EBUS could broaden Ion's pulmonary diagnostic capabilities and expand its addressable market.
Intuitive Surgical’s (ISRG - Free Report) Ion robotic platform is increasingly emerging as a meaningful second growth engine alongside the company’s core da Vinci franchise. In the second quarter of 2026, Ion procedures increased 36% year over year to 48,000, demonstrating that adoption is accelerating even as the much larger da Vinci platform continues to dominate Intuitive Surgical’s procedure base. Cumulative Ion procedures have now surpassed 400,000, providing a growing body of clinical experience that can support physician confidence, training and broader adoption.
Ion’s installed base rose 21% year over year, creating a larger foundation for recurring procedure growth and expanding adoption among hospitals and physicians. Intuitive is also expanding Ion internationally, with the system now available in 12 countries outside the United States. This broadens its geographic growth runway and reduces reliance on domestic procedure growth.
The longer-term opportunity is particularly compelling because Ion is positioned around lung cancer diagnosis, an area where earlier and more accurate detection can potentially improve patient management. Lung cancer is the second fastest growing cancer type globally, indicating a robust growth potential.
Management continues to invest in technologies designed to expand Ion’s clinical utility, including ROSE and EBUS. These programs are designed to enhance the platform’s pulmonary diagnostic capabilities and potentially expand the range of procedures that can be performed using the Ion ecosystem.
From an investment perspective, Ion’s importance extends beyond its current revenue contribution. The combination of rapid procedure growth, a rising installed base, international expansion and additional diagnostic capabilities creates strong potential for compounding growth.
If ROSE and EBUS broaden clinical applications, Ion could evolve into a more comprehensive lung-diagnostic ecosystem. This would broaden its addressable market, strengthen Intuitive Surgical’s technology moat and create another platform for sustained procedure growth and recurring instrument-and-accessory revenues.
Peer Updates
Medtronic’s (MDT - Free Report) next growth engine is a portfolio of newer platforms, with Cardiac Ablation Solutions (“CAS”) standing out. CAS sales grew 88% in the first quarter of fiscal 2027, supported by Sphere-9, whose U.S. market share increased nine points sequentially. Management expects CAS to grow more than 2.5x the mid-teens market.
Robotics is another key growth driver with strong potential. Medtronic is complementing its Hugo platform with Touch Surgery Aide, enhanced instrumentation and Cornerstone’s Sentire system in select international markets.
In spine, AiBLE ecosystem and Stealth AXiS are early-stage growth drivers, while Symplicity’s transradial catheter could accelerate renal denervation adoption. Together, these platforms provide Medtronic with multiple avenues to gain market share and expand its addressable market.
Boston Scientific’s (BSX - Free Report) strongest future growth engine appears to be its electrophysiology (EP) portfolio, where next-generation products are designed to broaden both its ecosystem and addressable patient population.
Boston Scientific plans to launch FARAPULSE Ultra at scale in 2027 while expanding into the rapidly growing ICE market. The company is also developing next-generation FARAFLEX Ultra platform, which is likely to be available in 2028. These launches should complement FARAPOINT and existing FARAPULSE capabilities, with management expecting EP growth to strengthen in late 2027 and 2028.
Boston Scientific is expected to close the acquisition of Penumbra in the second half of 2027, which is likely to add growth drivers beyond EP. Penumbra’s portfolio is expected to strengthen cardiovascular growth following its planned acquisition, while the MiRus investment provides an option to enter TAVR.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 35.3% so far this year compared with an 8.6% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 31.71X, above the industry average. However, it is significantly lower than its five-year median of 68.26X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Shutterstock
ISRG's Ion Platform Is Quietly Becoming a Second Growth Engine
Key Takeaways
Intuitive Surgical’s (ISRG - Free Report) Ion robotic platform is increasingly emerging as a meaningful second growth engine alongside the company’s core da Vinci franchise. In the second quarter of 2026, Ion procedures increased 36% year over year to 48,000, demonstrating that adoption is accelerating even as the much larger da Vinci platform continues to dominate Intuitive Surgical’s procedure base. Cumulative Ion procedures have now surpassed 400,000, providing a growing body of clinical experience that can support physician confidence, training and broader adoption.
Ion’s installed base rose 21% year over year, creating a larger foundation for recurring procedure growth and expanding adoption among hospitals and physicians. Intuitive is also expanding Ion internationally, with the system now available in 12 countries outside the United States. This broadens its geographic growth runway and reduces reliance on domestic procedure growth.
The longer-term opportunity is particularly compelling because Ion is positioned around lung cancer diagnosis, an area where earlier and more accurate detection can potentially improve patient management. Lung cancer is the second fastest growing cancer type globally, indicating a robust growth potential.
Management continues to invest in technologies designed to expand Ion’s clinical utility, including ROSE and EBUS. These programs are designed to enhance the platform’s pulmonary diagnostic capabilities and potentially expand the range of procedures that can be performed using the Ion ecosystem.
From an investment perspective, Ion’s importance extends beyond its current revenue contribution. The combination of rapid procedure growth, a rising installed base, international expansion and additional diagnostic capabilities creates strong potential for compounding growth.
If ROSE and EBUS broaden clinical applications, Ion could evolve into a more comprehensive lung-diagnostic ecosystem. This would broaden its addressable market, strengthen Intuitive Surgical’s technology moat and create another platform for sustained procedure growth and recurring instrument-and-accessory revenues.
Peer Updates
Medtronic’s (MDT - Free Report) next growth engine is a portfolio of newer platforms, with Cardiac Ablation Solutions (“CAS”) standing out. CAS sales grew 88% in the first quarter of fiscal 2027, supported by Sphere-9, whose U.S. market share increased nine points sequentially. Management expects CAS to grow more than 2.5x the mid-teens market.
Robotics is another key growth driver with strong potential. Medtronic is complementing its Hugo platform with Touch Surgery Aide, enhanced instrumentation and Cornerstone’s Sentire system in select international markets.
In spine, AiBLE ecosystem and Stealth AXiS are early-stage growth drivers, while Symplicity’s transradial catheter could accelerate renal denervation adoption. Together, these platforms provide Medtronic with multiple avenues to gain market share and expand its addressable market.
Boston Scientific’s (BSX - Free Report) strongest future growth engine appears to be its electrophysiology (EP) portfolio, where next-generation products are designed to broaden both its ecosystem and addressable patient population.
Boston Scientific plans to launch FARAPULSE Ultra at scale in 2027 while expanding into the rapidly growing ICE market. The company is also developing next-generation FARAFLEX Ultra platform, which is likely to be available in 2028. These launches should complement FARAPOINT and existing FARAPULSE capabilities, with management expecting EP growth to strengthen in late 2027 and 2028.
Boston Scientific is expected to close the acquisition of Penumbra in the second half of 2027, which is likely to add growth drivers beyond EP. Penumbra’s portfolio is expected to strengthen cardiovascular growth following its planned acquisition, while the MiRus investment provides an option to enter TAVR.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 35.3% so far this year compared with an 8.6% decline of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 31.71X, above the industry average. However, it is significantly lower than its five-year median of 68.26X. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 20.3% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.